PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

NCT05922904 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

DRUG: Brentuximab vedotin
DRUG: Doxorubicin Hydrochloride
DRUG: Pembrolizumab
DRUG: Dacarbazine

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]